Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Changsheng Bio Delisted following Major Vaccine Scandal

publication date: Oct 9, 2019

Changsheng Biotechnology, a Jilin vaccine biotech, will be delisted from the Shenzhen Stock Exchange one year after the company was discovered to be selling substandard vaccines. Investigators found that Changsheng Bio fabricated records for an inspection and that its DPT (diphtheria, pertussis, and tetanus) vaccine for children was largely ineffective. China has declared war on drug/vaccine companies that sell substandard products -- regulators want to build confidence in domestic drug products -- and the delisting shows the country's resolve. More details....

Stock Symbol: (SHZ: 002680)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.